ArticleBMC pregnancy and childbirth2025
Risk factors for acute fatty liver of pregnancy complicated by acute liver failure: a retrospective study of 133 cases.
Article in BMC pregnancy and childbirth, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Plasmapheresis for Suspected Drug-Induced Liver Injury During Pregnancy: A Multidisciplinary Diagnostic and Therapeutic Challenge.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectiveTo investigate the clinical manifestations and trends in laboratory indices in patients with acute fatty liver of pregnancy (AFLP) and identify risk factors for AFLP complicated by acute liver failure (ALF) to improve perinatal outcomes for these patients and their infants.
methodsClinical data, laboratory indices, and maternal and fetal outcomes for 133 patients with AFLP treated at our institution between January 1, 2010 and October 1, 2022 were retrospectively analyzed.
resultsThe most frequent clinical manifestations of AFLP were anorexia (n = 59, 44.4%), nausea (n = 41, 30.8%), and vomiting (n = 35, 26.3%). Liver function tests were significantly elevated, including serum alanine aminotransferase (287.0 ± 280.0 U/L), aspartate aminotransferase (254.0 ± 245.9 U/L), total bilirubin (99.1 ± 7.4 µmol/L), and direct bilirubin (84.3 ± 5.9 µmol/L). There was also marked coagulopathy, with a fibrinogen level of 1.7 ± 1.0 g/L and a prothrombin time of 16.7 ± 7.5 s. The main complication was acute liver failure (n = 33, 24.8%). Multivariate logistic regression analysis identified total bilirubin (OR 1.01, 95% CI 1.01-1.02, P < 0.001), direct bilirubin (OR 1.01, 95% CI 1.01-1.02, P < 0.001), prothrombin time (OR 1.20, 95% CI 1.09-1.32, P < 0.001), and activated partial thromboplastin time (OR 1.02, 95% CI 1.00-1.04, P = 0.017) to be risk factors for acute liver failure in patients with AFLP.
conclusionsAnorexia, nausea, and vomiting were the most common clinical manifestations of AFLP. Liver dysfunction and coagulopathy were indicated by changing trends in laboratory markers. Deterioration of liver function and coagulation parameters may be risk factors for acute liver failure in AFLP. Close monitoring of liver function and coagulation in patients with suspected or confirmed AFLP is essential to prevent this potentially lethal complication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.